Ph.D., VP, Operations and Data Science, ChromaCode, Inc.
Biography
Dr. MacDonald currently leads ChromaCode’s Data Science and Operations efforts. He is an experienced engineer and manager in the life sciences industry focused on data science, product engineering and process development. He is interested in using modern data science and machine learning approaches to complement tried-and-true industry standard methods for robust design like Design for Six Sigma. His PhD training was in Bioengineering, where he did computational neuroscience work modeling inter-cellular signaling mechanisms in neuro-glial networks at UC San Diego. At Illumina, he was an engineering manager responsible for product engineering and process development for consumables across several major platforms including HiSeqX, helping enable the $1000 genome. He developed numerous tools to monitor and understand the real time performance of worldwide sequencing runs in the cloud and drive continuous product improvement.
Clinical DX Showcase:
ChromaCode, Inc.
ChromaCode is redefining molecular testing through data science by increasing the information content of existing PCR and dPCR tests by 10x, enabling complex precision medicine tests on existing simple, robust technology.
10x Your Diagnostic Tool With Information Theory
We encode more information into existing diagnostic technologies (PCR) using novel data-science and informatics methods. This approach can revolutionize currently existing, stable diagnostic methods as it enables direct translation of complex applications onto existing diagnostics infrastructure.
Session Abstract – PMWC 2020 Silicon Valley
Track 6 - January 22 2.30 P.M.-3.45 P.M.,Track 7 - January 23 1.15 P.M.-1.30 P.M.,Track 6 - January 24 9.00 A.M.-1.15 P.M.
The PMWC 2020 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
